Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2019-000474
Abstract: Background Type 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well as potent T cell priming ability. Tissue-resident cDC1s (CD103+ cDC1s in mice, CD141+ cDC1s in humans) are linked with… read more here.
Keywords: cd103 cdc1s; vitro generated; generated cd103; cdc1s ... See more keywords
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
Sign Up to like & getrecommendations! Published in 2022 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2021-004309
Abstract: Background Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8+ T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal… read more here.
Keywords: human cdc1s; tumor antigen; xcl1 cc3; cdc1s ... See more keywords